tldrdaily.news logo
Tag

Eisai

All articles tagged with #eisai

healthcare1 year ago

Eisai Anticipates Significant Growth with China Alzheimer's Launch

Eisai plans to launch its Alzheimer's drug Leqembi to 1,500 patients in China this year, with expectations of significant growth in 2025 as more convenient blood tests become available. Eli Lilly is also developing a similar treatment and has filed for approval in China. The introduction of blood tests is expected to increase interest in the treatment. However, China's healthcare system is currently ill-prepared to provide timely access to Alzheimer's treatments, with limited diagnosis and treatment rates and a lack of specialty care in rural areas.

via Reuters|
#alzheimers#china#eisai
health2 years ago

"Breakthrough Alzheimer's Treatment Leqembi Receives Approval in Japan"

Japan's health ministry has approved the Alzheimer's treatment Leqembi, developed by Eisai and Biogen, making it the second country after the United States to clear its use. Leqembi is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of Alzheimer's patients and is the first treatment shown to slow the progression of the disease in the earlier stages. Eisai will conduct a post-marketing special use results survey to collect data on patients administered with Leqembi. The drug will be co-promoted by Eisai and Biogen in Japan.

via Reuters|
#alzheimers-treatment#biogen#eisai
healthcare2 years ago

Merck and Eisai halt Keytruda-Lenvima trial in head and neck cancer due to disappointing results

Merck and Eisai have decided to halt a Phase III clinical trial studying the combination of Keytruda and Eisai's Lenvima in head and neck squamous cell carcinoma. The decision was made after an interim analysis showed that the combination did not improve overall survival compared to Keytruda and placebo in patients with PD-L1 expressing tumors. As the study was unlikely to meet its primary endpoint, the trial was stopped.

via Endpoints News|
#clinical-trial#eisai#healthcare
healthcare2 years ago

"From Failures to Hope: FDA Approves Groundbreaking Alzheimer's Drug"

Eisai, the Japanese biotech company behind the newly approved Alzheimer's drug Leqembi, sees the approval as a catalyst in a competitive market. Leqembi showed a 27% reduction in cognitive decline in patients after 18 months and received full approval, expanding access for Alzheimer's patients. However, competitor Eli Lilly announced its treatment, donanemab, showed a 35% reduction in cognitive decline. Both drugs target the reduction of beta-amyloid plaques in the brain. Eisai is focused on expanding access for Leqembi to earlier-stage patients and believes it has set the bar for competitors in terms of price and data transparency.

via Yahoo Finance|
#alzheimers#biogen#drug-approval
healthcare2 years ago

Breakthrough Alzheimer's Drug Receives Government Approval, Faces Challenges Ahead

The FDA has granted full approval for a new Alzheimer's drug developed by Biogen and Eisai, paving the way for Medicare coverage and increased patient access. However, the road ahead remains challenging, as the drug faces burdensome caveats, including close patient monitoring and data collection for adverse events. The high costs of the treatment could also pose political challenges and competition from other drugs. Despite these obstacles, Wall Street remains cautiously optimistic, with some analysts highlighting potential upside for healthcare companies involved in home infusion services.

via Yahoo Finance|
#alzheimers#biogen#eisai
health2 years ago

FDA Approves Groundbreaking Drug to Slow Alzheimer's Disease

The FDA has granted approval to Leqembi, a drug developed by Japanese drugmaker Eisai and US-based Biogen, making it the first approved treatment that can slow the progression of Alzheimer's. Leqembi works by reducing amyloid plaques in the brain, addressing the underlying biology of the disease. However, it is not a cure and requires professional administration every two weeks. The drug's high cost of $26,500 per year may limit accessibility, with Medicare unlikely to cover it. The number of Americans with Alzheimer's is expected to increase, leading to a greater focus on treatments and diagnostics for the disease.

via Engadget|
#alzheimers#biogen#eisai
health2 years ago

FDA panel to review approval of Alzheimer's drug Leqembi

A panel of independent advisors to the FDA is meeting to decide whether the Alzheimer's drug Leqembi, made by Eisai and Biogen, should receive full approval. The FDA is expected to make a final decision on Leqembi on July 6. Leqembi is technically already available on the U.S. market after receiving fast-track approval in January, but very few seniors can access the expensive treatment because Medicare is restricting coverage to only people who are participating in clinical trials.

via CNBC|
#alzheimers#biogen#eisai
healthcare2 years ago

The Future of Alzheimer's Treatment: Promising Drugs and Blockbuster Stocks.

Eli Lilly's experimental Alzheimer's treatment, donanemab, is expected to gain approval and generate $465 million in sales in 2024, with projected sales of $1.4 billion and $3.2 billion in 2025 and 2030, respectively. The company is also working on a subcutaneous shot and an oral treatment for Alzheimer's disease. Analysts expect Medicare officials to sign off on reimbursement for donanemab and other anti-amyloid beta Alzheimer's treatments. Biogen and Eisai's Leqembi, which gained FDA accelerated approval in January, is a potential rival to donanemab.

via Investor's Business Daily|
#alzheimers-treatment#biogen#donanemab